People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Other, Biotechnology, Healthtech, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fluent, Inc. | — | Other | Series D+ | $264.9M | $97.2M | 2015 |
| ChromaDex Corp. | — | Biotechnology | Series B | $110.4M | $46.9M | 2013 |
| usell.com, Inc. | — | Other | Series B | $48.1M | $85.6M | 2011 |
| Odyssey Wellness LLC | — | Healthtech | Series A | $25.0M | $14.5M | 2023 |
| Polarityte, Inc. | — | Biotechnology | Series B | $24.0M | $69.4M | 2016 |
| Best One, Inc. | — | Other Technology | Series A | $6.2M | $171.4M | 2014 |
MICHAEL BRAUSER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MICHAEL BRAUSER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Barry Honig | 3 | 6 |
| Daniel Brauser | 3 | 3 |
| Steven Rubin | 2 | 7 |
| Scott Frohman | 2 | 4 |
| Peter Benz | 2 | 4 |
| James Reilly | 2 | 4 |
| Robert Fried | 2 | 2 |
| Derek Dubner | 2 | 2 |
| ROBERT N FRIED | 2 | 2 |
| Steve Gorlin | 1 | 11 |
| Steven D. Rubin | 1 | 9 |
| Mark Friedman | 1 | 8 |
| Jeff Baxter | 1 | 4 |
| John Stetson | 1 | 3 |
| Peter Cohen | 1 | 3 |
| Thomas Varvaro | 1 | 3 |
| Jason Rubin | 1 | 3 |
| David Graff | 1 | 3 |
| Glenn L. Halpryn | 1 | 3 |
| Stephen Block | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.